Invention:
This invention is a method of synthesis of novel Au(II) dimer with pyridine dipyrrolinone (H2PYDP) ligands which demonstrate antiproliferative activity in ovarian cancers. This compound operates with a different mechanism than similar existing drugs allowing for novel combinational drug therapies to be created and tested.
Background:
It is estimated that in 2024, about 19,680 women will receive a new diagnosis of ovarian cancer and about 12,740 women will die from ovarian cancer. For those in remission, more than 80% of ovarian cancer patients experience recurrent disease, and more than 50% of these patients die from the disease in less than five years post-diagnosis. For years, cisplatin and other platinum-based anticancer drugs have remained the drugs of choice for treating ovarian cancer with a variety of combinational options. Despite the initial success of these drugs, cisplatin falls short in its ability to maintain efficacy. To address the resistance to cisplatin, these novel Au(II) dimers with newer mechanistic approaches are likely to provide new avenues for ovarian cancer therapies.
Applications:
- Ovarian cancer therapeutic
- Anticancer therapeutic
- Cisplatin-resistant cancer
Advantages:
- Increased antiproliferative activity to prevent regrowth of cancer cells
- New mechanistic properties allowing for alternative approaches
- New opportunities for combinational therapies
- Addresses cisplatin resistance
